Mazdutide and tirzepatide are both dual receptor agonists given as once-weekly injections, but they pair GLP-1 with a different second receptor and are approved in different places. Tirzepatide is FDA-approved, while mazdutide gained China NMPA approval in 2025 but is not FDA- or EMA-approved, so use outside China is investigational.
Reviewed for accuracy · Last reviewed July 8, 2026The clearest practical difference is regulatory geography. Tirzepatide is FDA-approved with a defined label and titration, whereas mazdutide gained China NMPA approval in 2025 for weight management and glycemic control but is not FDA- or EMA-approved, so any use outside China is investigational and unlabeled.
Mechanistically the two differ in their second target. Both use GLP-1, but mazdutide pairs it with glucagon (thought to add energy expenditure and liver-fat effects), while tirzepatide pairs it with GIP. Mazdutide's evidence also comes largely from Chinese trial populations, which may limit how well it generalizes. Whether either receptor pairing is preferable in practice is not something the current evidence lets anyone state as fact.
Both were studied as once-weekly subcutaneous injections with gradual dose escalation, and both reported predominantly dose-related gastrointestinal side effects. Neither of these summaries is a substitute for medical advice about which, if either, is appropriate.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.